Emerging Immunotargets in Metastatic Renal Cell Carcinoma

Author(s): John Kucharczyk, Marc R. Matrana, Matteo Santoni, Francesco Massari, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Stefano Cascinu, Rodolfo Montironi, Moch Holger.

Journal Name: Current Drug Targets

Volume 17 , Issue 7 , 2016

  Journal Home
Translate in Chinese
Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Renal cell carcinoma (RCC) is one of the most immunoresponsive human cancers. High-dose IL-2 and Interferon-α were once the principle therapies for metastatic RCC, however they had harsh-tolerance profiles and limited response rates. In the last decade, targeted therapies have supplanted cytokine therapy due to higher response rates and more favorable toxicity profiles. Emerging immunotherapies targeting the PD-1 receptor and PD-L1 ligand have shown promising results. Likewise, other novel targeted immunotherapies are currently under evaluation. The safety profiles and response rates of new generation immunotherapies are encouraging and justify the progression of clinical trials. However, longer follow-up data are needed to confirm these promising results. In addition, it is still unclear if an optimal sequence or combinations of new immunotherapies paired with current targeted therapies will emerge.

Keywords: Immunotherapy, immunotargets, metastatic renal cell carcinoma, kidney cancer.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 7
Year: 2016
Page: [771 - 776]
Pages: 6
DOI: 10.2174/1389450117666151209115753
Price: $58

Article Metrics

PDF: 36
HTML: 4
EPUB: 1
PRC: 1